Skip to main content

Main results compared to Q1 2018:

  • 19.5% increase in revenues
  • 49% increase in operating profit
  • 23% increase in net profit. 

''We are pleased to report strong results today in a period of intense competition. Pharming’s revenue and profit performance confirm the success of our in-market strategy for RUCONEST® as we see continued growth in underlying demand for the product.''

- Sijmen de Vries - CEO
Cookies: This website uses cookies Check the cookies page for more information Accept Decline